Repeat treatment of Rheumatoid Arthritis patients with a murine anti‐intercellular adhesion molecule 1 monoclonal antibody

• Published in: Arthritis and rheumatism 1997-05, Vol.40 (5), p.849-853
• Main Authors: Kavanaugh, Arthur F., Schulze‐Koops, Hendrik, Davis, Laurie S., Lipsky, Peter E.
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Arthritis, Rheumatoid - therapy; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Headache - chemically induced; Humans; Intercellular Adhesion Molecule-1 - immunology; Interferon-gamma - blood; Interferon-gamma - genetics; Interleukin-2 - blood; Interleukin-2 - genetics; Interleukin-4 - blood; Interleukin-4 - genetics; Medical sciences; Mice; Nausea - chemically induced; Pharmacology. Drug treatments; Receptors, Interleukin-2 - blood; Receptors, Interleukin-2 - genetics; RNA, Messenger - metabolism; Treatment Outcome; Urticaria - chemically induced; von Willebrand Factor - analysis
• ISSN: 0004-3591; 1529-0131
• DOI: 10.1002/art.1780400511

Objective. To assess the safety and efficacy of a second course of treatment with a murine monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM‐1; CD54) in active rheumatoid arthritis (RA). Methods. In an open‐label study, 8 patients who had previously received a course of anti‐ICAM‐1 MAb received a second course. Results. The second course of therapy was associated with adverse effects suggestive of immune complex formation. Such adverse effects were not seen during the initial course of therapy. Clinical efficacy associated with the second course of therapy was less than that observed in the first course. Conclusion. Repeated courses of therapy with a murine MAb to ICAM‐1 would probably not be a useful therapeutic strategy in patients with RA, probably because of its immunogenicity.